Anavex Life Sciences Corp (AVXL)

[bas2020]

The statements below, from the 2018 study with Ariana's KEM analysis, make it rather clear that they most certainly designed the P2b/3 AD trial to include all the necessary gene selection criteria, with pre-specified biomarkers to make it a pivotal trial, with all endpoints being met.

Ariana’s KEM® Artificial Intelligence technology has resulted in the identification of the first actionable genetic variant biomarkers, selecting a specified Alzheimer’s disease population, who demonstrated a confirmed response with ANAVEX®2-73.

These results provide support for a faster precision medicine clinical development of ANAVEX®2-73 focusing on the right patients who could benefit from the drug.

“This is the first full genomic analysis of ANAVEX®2-73 in Alzheimer’s disease which resulted in the identification of actionable genetic variants, bringing us one step closer to realizing the full potential of a precision medicine and precision pharmacology approach to treating this devastating disease,” Professor Harald Hampel, M.D., Ph.D., MA, MSc, AXA Research Fund & Sorbonne University Excellence Chair, Department of Neurology, Sorbonne University, Paris.